1. Home
  2. LIVN vs HRMY Comparison

LIVN vs HRMY Comparison

Compare LIVN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIVN
  • HRMY
  • Stock Information
  • Founded
  • LIVN 1987
  • HRMY 2017
  • Country
  • LIVN United Kingdom
  • HRMY United States
  • Employees
  • LIVN N/A
  • HRMY N/A
  • Industry
  • LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • LIVN Health Care
  • HRMY Health Care
  • Exchange
  • LIVN Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • LIVN 2.1B
  • HRMY 2.0B
  • IPO Year
  • LIVN 1993
  • HRMY 2020
  • Fundamental
  • Price
  • LIVN $44.10
  • HRMY $35.31
  • Analyst Decision
  • LIVN Strong Buy
  • HRMY Strong Buy
  • Analyst Count
  • LIVN 7
  • HRMY 9
  • Target Price
  • LIVN $59.29
  • HRMY $54.22
  • AVG Volume (30 Days)
  • LIVN 938.0K
  • HRMY 738.5K
  • Earning Date
  • LIVN 07-30-2025
  • HRMY 05-06-2025
  • Dividend Yield
  • LIVN N/A
  • HRMY N/A
  • EPS Growth
  • LIVN N/A
  • HRMY 13.13
  • EPS
  • LIVN N/A
  • HRMY 2.62
  • Revenue
  • LIVN $1,275,380,000.00
  • HRMY $744,852,000.00
  • Revenue This Year
  • LIVN $8.10
  • HRMY $20.35
  • Revenue Next Year
  • LIVN $5.76
  • HRMY $17.42
  • P/E Ratio
  • LIVN N/A
  • HRMY $13.46
  • Revenue Growth
  • LIVN 7.62
  • HRMY 20.62
  • 52 Week Low
  • LIVN $32.48
  • HRMY $26.47
  • 52 Week High
  • LIVN $61.40
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • LIVN 59.34
  • HRMY 61.62
  • Support Level
  • LIVN $42.44
  • HRMY $33.47
  • Resistance Level
  • LIVN $43.61
  • HRMY $35.35
  • Average True Range (ATR)
  • LIVN 1.01
  • HRMY 1.09
  • MACD
  • LIVN -0.16
  • HRMY -0.01
  • Stochastic Oscillator
  • LIVN 66.62
  • HRMY 70.34

About LIVN LivaNova PLC

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: